The use of corticosteroids in the luteal phase of in vitro fertilization (IVF) cycles has been a classic theme in clinical research. The treatment schedules showed great variability but most studies started corticoid therapy from oocyte retrieval and kept it up for 14 days. It is important to mention that in assessing the studies one considered the following clinical outcomes: live birth rate; pregnancy rate; implantation rate; and adverse events. A randomized controlled trial (RCT) carried out in patients with endometriosis who had non-organ specific autoantibodies showed that the administration of glucocorticoids was associated with significantly higher pregnancy rates. Corticoid treatment is useful in improving ovarian response to stimulation in patients with a poor response. The additional benefit observed in patients who have undergone assisted hatching is of little clinical value as there are few indications for applying this technique, either routinely or in specific indications.